Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
University of California, San Francisco
National Cancer Institute (NCI)
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Beijing Biotech
Jazz Pharmaceuticals
Bayer
Pfizer
National Institutes of Health Clinical Center (CC)
AstraZeneca
Memorial Sloan Kettering Cancer Center
Imperial College London
Eli Lilly and Company
Filamon LTD
Origin Sciences
AstraZeneca
UMC Utrecht
Psyence Australia Pty Ltd
ViroMissile, Inc.
Dana-Farber Cancer Institute
Tasca Therapeutics
Essen Biotech
MBrace Therapeutics
Azienda Ospedaliero-Universitaria di Parma
A2 Biotherapeutics Inc.
Angiex, Inc.
MacroGenics
Daiichi Sankyo
University of Nebraska
Adela, Inc
Natera, Inc.
Var2 Pharmaceuticals
Mayo Clinic
Degron Therapeutics Co.
Cancer Research UK
Dana-Farber Cancer Institute
Massive Bio, Inc.
Memorial Sloan Kettering Cancer Center
Maastricht University Medical Center
Institut Bergonié
GI Innovation, Inc.
Exelixis
Senhwa Biosciences, Inc.
Jonsson Comprehensive Cancer Center
Shanghai Public Health Clinical Center
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
Cancer Research UK
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Monopar Therapeutics